1 / 1

Spinal Muscular Atrophy Drug Pipeline - 2012

Clinical Development. Preclinical: Discovery. Spinal Muscular Atrophy Drug Pipeline - 2012. FDA Approval. Basic Research Seed Ideas. Identification Optimization Safety & Manufacturing. Phase I Phase II Phase III. IND. Trophos/Olesxime. Repligen/Quinazoline*.

Download Presentation

Spinal Muscular Atrophy Drug Pipeline - 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Clinical Development Preclinical: Discovery Spinal Muscular Atrophy Drug Pipeline - 2012 FDA Approval Basic Research Seed Ideas Identification Optimization Safety & Manufacturing Phase I Phase II Phase III IND Trophos/Olesxime Repligen/Quinazoline* ISIS - Biogen/Antisense* CSC/Motor Neuron* OSU/Gene Therapy* NINDS/Indoprofen Paratek/Tetracycline* *Projects with FSMA FundingInvolvement PTC - Roche/SMN Regulators Novartis/SMN Regulators Repurposed Drugs Studied for SMA Valproic Acid* Riluzole Phenylbutyrate* Hydroxyurea Salbutamol CALiBR SMN Regulators NCGC - IU/SMN Regulators NINDS/Benzimidazoles Harvard /SMN Regulators IU = Indiana University NCGC = NIH Chemical Genomics Center NINDS = National Institute of Neurological Disorders and Stroke

More Related